Epix Pharmaceuticals of Cambridge, MA, has submitted a formal appeal to the U.S. Food and Drug Administration to approve the company's blood-pool imaging agent Vasovist.
Vasovist is an injectable, intravascular contrast agent designed to provide visual imaging of the vascular system through MR angiography. Epix is targeting an initial indication for imaging of noncoronary vascular disease.
In October 2005, the European Medicines Agency granted marketing approval of Vasovist for all 25-member states of the European Union. Epix's Vasovist partner, Schering of Berlin, began marketing the imaging agent in Europe in the second quarter this year.
By AuntMinnie.com staff writers
July 4, 2006
Related Reading
Astrue resigns from Epix, May 8, 2006
Epix to buy Predix Pharmaceuticals, April 3, 2006
Epix adds VPs, February 23, 2006
Sales fall, losses grow for Epix in ’05, February 16, 2006
Schering options joint Epix-Schering agent, February 13, 2006
Copyright © 2006 AuntMinnie.com
